Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: a meta-analysis in Europeans
Matthias M. Mauschitz
(1)
,
Timo Verzijden
(2)
,
Alexander K. Schuster
(3)
,
Hisham Elbaz
(3)
,
Norbert Pfeiffer
(3)
,
Anthony Khawaja
(4)
,
Robert N. Luben
(4)
,
Paul J. Foster
(4)
,
Franziska G. Rauscher
(5)
,
Kerstin Wirkner
(5)
,
Toralf Kirsten
(5)
,
Jost B. Jonas
(6)
,
Mukharram M. Bikbov
(7)
,
Ruth Hogg
(8)
,
Tunde Peto
(4)
,
Audrey Cougnard-Grégoire
(9)
,
Geir Bertelsen
(10)
,
Maja Gran Erke
(11)
,
Fotis Topouzis
(12)
,
Dimitrios A. Giannoulis
(12)
,
Caroline Brandl
(13)
,
Iris M. Heid
(13)
,
Catherine P. Creuzot‐Garcher
(14, 15)
,
Pierre-Henry Gabrielle
(14)
,
Hans-Werner Hense
(16)
,
Daniel Pauleikhoff
(17)
,
Patricia Barreto
(18)
,
Rita Coimbra
(18)
,
Stefano Piermarocchi
(19)
,
Vincent Daien
(20)
,
Frank G. Holz
(1)
,
Cecile Delcourt
(9)
,
Robert P. Finger
(1)
,
. On Behalf of The European Eye Epidemiology (e3) Consortium
1
University Hospital Bonn
2 Erasmus MC - Erasmus University Medical Center [Rotterdam]
3 University Medical Center [Mainz]
4 NIHR Biomedical Research Centre [London]
5 Leipzig University / Universität Leipzig
6 Universität Heidelberg [Heidelberg] = Heidelberg University
7 Ufa Eye Research Institute [Bashkortostan]
8 QUB - Queen's University [Belfast]
9 BPH - Bordeaux population health
10 UiT - The Arctic University of Norway [Tromsø, Norway]
11 Directorate of eHealth
12 Aristotle University of Thessaloniki
13 University of Regensburg
14 Service d'Ophtalmologie (CHU de Dijon)
15 CSGA - Centre des Sciences du Goût et de l'Alimentation [Dijon]
16 WWU - Westfälische Wilhelms-Universität Münster = University of Münster
17 St. Franziskus-Hospital
18 AIBILI - Association for Innovation and Biomedical Research on Light and Image
19 Padova-Camposampiero Hospital
20 Hôpital Gui de Chauliac [CHU Montpellier]
2 Erasmus MC - Erasmus University Medical Center [Rotterdam]
3 University Medical Center [Mainz]
4 NIHR Biomedical Research Centre [London]
5 Leipzig University / Universität Leipzig
6 Universität Heidelberg [Heidelberg] = Heidelberg University
7 Ufa Eye Research Institute [Bashkortostan]
8 QUB - Queen's University [Belfast]
9 BPH - Bordeaux population health
10 UiT - The Arctic University of Norway [Tromsø, Norway]
11 Directorate of eHealth
12 Aristotle University of Thessaloniki
13 University of Regensburg
14 Service d'Ophtalmologie (CHU de Dijon)
15 CSGA - Centre des Sciences du Goût et de l'Alimentation [Dijon]
16 WWU - Westfälische Wilhelms-Universität Münster = University of Münster
17 St. Franziskus-Hospital
18 AIBILI - Association for Innovation and Biomedical Research on Light and Image
19 Padova-Camposampiero Hospital
20 Hôpital Gui de Chauliac [CHU Montpellier]
Matthias M. Mauschitz
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1184210
Connectez-vous pour contacter l'auteur
Ruth Hogg
- Fonction : Auteur
- PersonId : 1184213
- ORCID : 0000-0001-9413-2669
Tunde Peto
- Fonction : Auteur
- PersonId : 1184214
- ORCID : 0000-0001-6265-0381
Maja Gran Erke
- Fonction : Auteur
- PersonId : 1184215
- ORCID : 0000-0002-7476-0286
Pierre-Henry Gabrielle
- Fonction : Auteur
- PersonId : 783994
- ORCID : 0000-0002-9688-4845
Vincent Daien
- Fonction : Auteur
- PersonId : 764204
- ORCID : 0000-0001-5675-0861
- IdRef : 16475900X
Cecile Delcourt
- Fonction : Auteur
- PersonId : 15525
- IdHAL : cecile-delcourt
- ORCID : 0000-0002-2099-0481
- IdRef : 035105291
. On Behalf of The European Eye Epidemiology (e3) Consortium
- Fonction : Auteur
Résumé
Background/aims To investigate the association of commonly used systemic medications with prevalent age-related macular degeneration (AMD) in the general population. Methods We included 38 694 adults from 14 population-based and hospital-based studies from the European Eye Epidemiology consortium. We examined associations between the use of systemic medications and any prevalent AMD as well as any late AMD using multivariable logistic regression modelling per study and pooled results using random effects meta-analysis. Results Between studies, mean age ranged from 61.5±7.1 to 82.6±3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and late AMD, respectively. In the meta-analysis of fully adjusted multivariable models, lipid-lowering drugs (LLD) and antidiabetic drugs were associated with lower prevalent any AMD (OR 0.85, 95% CI=0.79 to 0.91 and OR 0.78, 95% CI=0.66 to 0.91). We found no association with late AMD or with any other medication. Conclusion Our study indicates a potential beneficial effect of LLD and antidiabetic drug use on prevalence of AMD across multiple European cohorts. Our findings support the importance of metabolic processes in the multifactorial aetiology of AMD. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ⇒ These findings have implications for public health messages, underline the link of AMD with cardiovascular comorbidities and may provide potential future therapeutic targets.